FDA Inspection 1169068 — Medpace, Inc.
The FDA completed an inspection of Medpace, Inc. on April 26, 2022 in Cincinnati, OH. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- April 26, 2022
- Fiscal Year
- 2022
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Cincinnati, OH (United States)
Additional Details
Sponsor, Contract Research Organization